title: Pentostatin plus cyclophosphamide and bexarotene is an effective and safe combination in patients with mycosis fungoides/Sezary syndrome.
authors.forename: Cristina
authors.initials: C
authors.lastname: Calderon Cabrera
authors.forename: Fatima
authors.initials: F
authors.lastname: de la Cruz Vicente
authors.forename: Ana
authors.initials: A
authors.lastname: Marín-Niebla
authors.forename: Estrella
authors.initials: E
authors.lastname: Carrillo Cruz
authors.forename: Eduardo
authors.initials: E
authors.lastname: Rios Herranz
authors.forename: Ildefonso
authors.initials: I
authors.lastname: Espigado Tocino
authors.forename: Concepción
authors.initials: C
authors.lastname: Prats Martín
authors.forename: Jose F
authors.initials: JF
authors.lastname: Falantes
authors.forename: María L
authors.initials: ML
authors.lastname: Martino Galiana
authors.forename: Jose A
authors.initials: JA
authors.lastname: Perez-Simón
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000077610:Bexarotene; D003520:Cyclophosphamide / Q000008:administration & dosage; D006801:Humans; D009182:Mycosis Fungoides / Q000188:drug therapy*; D015649:Pentostatin / Q000008:administration & dosage; D012751:Sezary Syndrome / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy*; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D013764:Tetrahydronaphthalenes; D015649:Pentostatin; D003520:Cyclophosphamide; D000077610:Bexarotene